Regeneration, health status and quality of life after rhG-CSF-stimulated stem cell collection in healthy donors: a cross-sectional study

Leitner, Gerda; Baumgartner, Kathy B.; Kalhs, Peter; Biener, D.; Greinix, Hildegard; Hoecker, Paul; Worel, Nina

doi:10.1038/bmt.2008.335

Cited by 23 publications

(32 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fewer donors in our study (40-50%) experienced the side effects of G-CSF administration when compared with reports from other authors (50-90%). These data may be biased due to the subjective nature of the donors' complaints and also differences in the rating of the symptoms [18][19][20]. The frequency of apheresis-related complications was consistent with that previously described [18,19].…”

Section: Discussionsupporting

confidence: 82%

Efficacy and safety of peripheral blood stem cell collection in elderly donors; does age interfere?

Lysák¹,

Korístek

Gašová

et al. 2010

J. Clin. Apheresis

View full text Add to dashboard Cite

Elderly patients with hematological malignancies are often reliant on allogeneic transplantations. Older family relatives are increasingly involved in utilization as PBSC donors. We analyzed the mobilization results from 103 donors of age ≥55 years in comparison with 121 younger donors of age <55 years. The median CD34+ count in peripheral blood on day +5 of the mobilization was higher in younger than in older donor group (72.0 vs. 37.0 cells/μL, P < 0.0001). Linear regression showed a negative correlation between the age and CD34+ count in peripheral blood (P < 0.0001) and apheresis product (P < 0.0001). Based on multivariate analysis, the amount of circulating CD34+ cells appeared to be negatively influenced by age (P < 0.001) and positively by the preapheresis WBC count (P < 0.001). The precollection CD34+ (P < 0.0001), PLT (P = 0.0144) counts, and age (P = 0.0392) were confirmed as independent factors determining the collection yield. The side effects of G-CSF administration were similar in both the groups. Apheresis complications were more frequently recorded in elderly donors (29 vs. 15%, P = 0.0096). Higher age represents a risk factor for poorer mobilization results. A requirement for more than one apheresis in older donors occurs more frequently to obtain the adequate amount of CD34+ cells. Mobilization and collection procedures are associated with acceptable risks and complication rates in elderly donors.

show abstract

Section: Discussionsupporting

confidence: 82%

Efficacy and safety of peripheral blood stem cell collection in elderly donors; does age interfere?

Lysák¹,

Korístek

Gašová

et al. 2010

J. Clin. Apheresis

View full text Add to dashboard Cite

show abstract

“…The survey of Halter et al included 1 case of Hodgkin disease; another case has been reported by Leitner et al, both in male PBSC donors who were siblings of patients with hematologic malignancies. 16,34 The sample size investigated in our study is still far too small to allow any conclusion to be drawn. Therefore, although our data provide an interim analysis, they call for a prolonged and thorough follow-up of the increasing number of volunteer donors receiving rhG-CSF for PBSC mobilization.…”

Section: Discussionmentioning

confidence: 87%

“…To the best of our knowledge, this is the lowest frequency reported so far and may be attributed to the young age of our unrelated volunteer donors (median, 34 years) and the use of highly experienced staff. In the study of Leitner et al, 16 central venous access was needed in 2 of 171 (1.1%) related donors. This resembles our own experience in 328 related donors with a median age of 49 years (range, 5-74 years), 4 (1.2%) of whom required a central line.…”

Section: Discussionmentioning

confidence: 97%

“…In accordance with the literature, mobilization and harvest of CD34 ϩ cells were significantly more effective in male than in female donors. [16][17][18] Future research could identify genetic factors that would predict which donors are likely to fail adequate mobilization. One could envision alternative mobilization regimens 19 or decide for bone marrow collection.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors

Hölig

Kramer

Kroschinsky

et al. 2009

Blood

200

164

View full text Add to dashboard Cite

We present results of peripheral blood stem cell (PBSC) mobilization, collection, and follow-up from 3928 consecutive unrelated stem cell donors. Assessments were performed prospectively at baseline, leukapheresis, 1 month, 6 months, and annually after PBSC donation. During follow-up, side effects were recorded by return post questionnaires. The median CD34 ؉ cell counts on day 5 were 67.5/L in male and 51/L in female donors. Bone pain and headache were the most common side effects of recombinant human granulocyte-colony stimulating factor. Central venous access was required for 23 donations (0.6%). Throughout the follow-up, the absolute neutrophil counts were slightly below the initial baseline values but remained within the normal range. The majority of the donors reported good or very good health. Malignancies occurred in 12 donors (0.3%), among whom were 1 case of acute myeloid leukemia, 1 case of chronic lymphatic leukemia, and 2 cases of Hodgkin disease. Only the incidence of Hodgkin lymphoma differed significantly from an age-adjusted population. In conclusion, 7.5 g/kg per day lenograstim proved to be safe and effective for mobilizing hematopoietic stem cells for allogeneic transplantation. Long-term monitoring of healthy PBSC donors remains important to guarantee the safety standards of PBSC mobilization and collection.

show abstract

“…Large volume bone marrow (BM) harvest is an alternative to G-CSF-induced peripheral blood stem cell collection in patients or donors who are poor mobilizers, in the paediatric setting or in the regenerative medicine, when patients with myocardial infarction are intended to receive stem cells intracardially [1][2][3][4]. Donors and patients are at risk to develop a severe anaemia because collected BM can contain up to 20% of their red cell mass.…”

Section: Introductionmentioning

confidence: 99%

Red blood units collected from bone marrow harvests after mononuclear cell selection qualify for autologous use

et al. 2010

View full text Add to dashboard Cite

Background After large volume bone marrow (BM) harvest, donors and patients can develop severe anaemia, because collected BM can contain up to 20% of their red cell mass. In a prospective analysis, we investigated the feasibility to recover red blood cells (RBCs) from the harvested BM and investigated whether these RBC units meet the quality requirements of the European Council.Patients and Methods From 19 patients (median age 51 yrs, range 31-77) with acute myocardial infarction, who participated in the MYSTAR study, a median volume of 1299 ml (range, 700-1870 ml) BM was collected. During BM processing, mononuclear cells (MNC) were separated using the Cobe SpectraÔ apheresis system and the residual RBCs were collected in a separate bag. The quality of the collected RBCs was assessed by measuring LDH, free haemoglobin, potassium and lactate. Haemolysis was calculated and the intracellular concentration of ATP, ADP, AMP was determined by HPLC.Results RBC units recovered from BM after MNC separation had a mean volume of 312 ± 95 ml with a haematocrit of 47 ± 8AE9%, a haemoglobin content of 51 ± 15 g per unit, a haemolysis of 0AE15 ± 0AE005%, a pH of 6AE8 ± 0AE007 and an intracellular ATP concentration of 135 pmol ⁄ 10 6 RBC ± 41, which is comparable with freshly collected packed red blood cells (PRBCs).Conclusion RBCs, collected from bone marrow harvests, can be used for autologous blood support to minimize allogeneic blood transfusions in donors and patients after large volume BM donation.Key words: blood sparing measurements, bone marrow harvest, bone marrow processing, salvage of red blood cells. IntroductionLarge volume bone marrow (BM) harvest is an alternative to G-CSF-induced peripheral blood stem cell collection in patients or donors who are poor mobilizers, in the paediatric setting or in the regenerative medicine, when patients with myocardial infarction are intended to receive stem cells intracardially [1][2][3][4]. Donors and patients are at risk to develop a severe anaemia because collected BM can contain up to 20% of their red cell mass. To reduce the risk of anaemia after BM donation, at least one unit of autologous blood should be collected prior to the harvest procedure [5]. Alternatively, certain clinicians place the donors on supplemental iron plus rhEPO, transfuse their donors with allogeneic RBC units or tolerate anaemia when not severe [6]. Previous studies have shown that a recovery of approximately 90% of the harvested BM-RBCs decreased the homologous transfusion requirement of healthy BM donors significantly [7]. When paediatric BM donors were investigated and BM-RBCs were separated by density gradient centrifugation using Ficoll-Hypaque, similar results were In a prospective analysis, we assessed the extent of cell lesions occurring during manipulation by measuring the release of lactate dehydrogenase (LDH), free haemoglobin (fHb), potassium (K+) and lactate at each manipulation step. Special attention was paid to intracellular purine content by measuring ATP, ADP, AMP, as a surrogate mar...

show abstract

Regeneration, health status and quality of life after rhG-CSF-stimulated stem cell collection in healthy donors: a cross-sectional study

Cited by 23 publications

References 28 publications

Efficacy and safety of peripheral blood stem cell collection in elderly donors; does age interfere?

Efficacy and safety of peripheral blood stem cell collection in elderly donors; does age interfere?

Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors

Red blood units collected from bone marrow harvests after mononuclear cell selection qualify for autologous use

Contact Info

Product

Resources

About